Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China · Delayed Price · Currency is CNY 27.30
-0.62 (-2.22%)
Apr 21, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Revenue
In the year 2025, Wuhan Hvsen Biotechnology had annual revenue of 1.68B CNY with 40.07% growth. Wuhan Hvsen Biotechnology had revenue of 421.71M in the quarter ending December 31, 2025, with 3.42% growth.
Revenue
1.68B
Revenue Growth
+40.07%
P/S Ratio
3.35
Revenue / Employee
1.64M
Employees
1,028
Market Cap
5.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.68B | 480.92M | 40.07% |
| Dec 31, 2024 | 1.20B | 180.57M | 17.71% |
| Dec 31, 2023 | 1.02B | -3.14M | -0.31% |
| Jan 1, 2023 | 1.02B | 26.68M | 2.68% |
| Jan 1, 2022 | 996.22M | 218.76M | 28.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.26B |
| Kexing Biopharm | 1.54B |
| Shenzhen Weiguang Biological Products | 1.14B |
| ChemPartner PharmaTech | 1.07B |
| Beijing Konruns Pharmaceutical | 871.31M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 502.95M |
| Hangzhou Biotest Biotech | 448.37M |